Jump to content

Tarceva Access (ACT) Trial Opens


Recommended Posts

Tarceva Access (ACT) Trial Opens

Genentech, Inc. and OSI Pharmaceuticals, Inc. have begun a Phase IIIB clinical study, called the ACT (Access to Care, Tarceva) trial, with the oral drug (pill) Tarceva (erlotinib HCl) in patients with non-small cell lung cancer for whom previous chemotherapy has failed. Designed to allow access to this investigational drug as the U.S. Food and Drug Administration (FDA) considers its approval, the study will eventually enroll eligible patients at about 50 hospitals nationally. There will be no charge for Tarceva used in the study, which is intended to measure survival and response rate. Enrollment will continue until the FDA's aproval decision.

For details on enrollment, other costs, and site locations, call Genentech's Trial Information Support Line at 888-662-6728.

To search for other trials, see Finding Clinical Trials on this website.

Frequently Asked Questions:

Who will be eligible for the ACT Trial?

The ACT Trial will make Tarceva available to certain patients who have a diagnosis of advanced or metastatic non-small cell lung cancer (NSCLC) that has progressed or relapsed after previous chemotherapy. Eligible patients cannot have had prior exposure to small molecule tyrosine kinase inhibitors (TKIs), including Tarceva or Iressa

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.